Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
The webcast will be archived for 30 days at the aforementioned URL.
Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX)
today announced that the Company will release its 2018 fourth quarter
and full year financial results on Thursday, February 28, 2019, before
the market opens.
Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial
Officer, will host a conference call to discuss the results as follows:
| Date | Thursday, February 28, 2019 | ||
| Time | 8:30 a.m. EDT | ||
| Toll free | (U.S.) 877-876-9177 | ||
| International | 785-424-1672 | ||
| Webcast (live and replay) |
www.eagleus.com, |
A replay of the conference call will be available for one week after the
call's completion by dialing 800-283-4799 (US) or 402-220-0860
(International) and entering conference call ID EGRXQ418. The webcast
will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and
commercializing injectable products that address the shortcomings, as
identified by physicians, pharmacists and other stakeholders, of
existing commercially successful injectable products. Eagle’s strategy
is to utilize the FDA's 505(b)(2) regulatory pathway. Additional
information is available on the company’s website at www.eagleus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190219005381/en/